Daré Bioscience (Cerulean Pharma) Priced, Nasdaq: DARE
Developing targeted therapies for kidney, ovarian and other cancers.
Industry: Health Care
First Day Return: -2.1%
Industry: Health Care
DARE
Developing targeted therapies for kidney, ovarian and other cancers.
| IPO Data | |
|---|---|
| IPO File Date | 03/10/2014 |
| Offer Price | $7.00 |
| Price Range $11.00 - $13.00 | |
| Offer Shares (mm) | 8.5 |
| Deal Size ($mm) | $60 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 04/09/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $60 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Cambridge, MA, United States |
| Founded | 2005 |
| Employees at IPO | 21 |
| Website www.ceruleanrx.com | |
IPO News for Daré Bioscience (Cerulean Pharma)
Daré Bioscience (Cerulean Pharma) (DARE) Performance
